# Elicio Therapeutics, Inc.: filings

ELTX · Nasdaq · CIK 1601485 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eltx.md) · [Financials](/companies/eltx/financials.md) · [Filings](/companies/eltx/filings.md) · [Insiders](/companies/eltx/insiders.md)

## Reports and events: 130 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 114, 8-K 79, 3 21, 10-Q 17, CORRESP 15, UPLOAD 11, SC 13D/A 9, D 8, EFFECT 8, 425 7, S-8 7, 10-K 6, 424B5 6, S-3 6, 4/A 4, DEF 14A 4, S-1/A 4, S-4/A 4, SC 13G 4, SC 13G/A 4, SEC STAFF LETTER 4, 10-K/A 3, 424B3 3, S-3/A 3, SC 13D 3, SCHEDULE 13G 3, SCHEDULE 13G/A 3, ARS 2, DRS 2, DRS/A 2, DRSLTR 2, S-1 2, SCHEDULE 13D/A 2, 3/A 1, 424B4 1, 8-A12B 1, 8-A12B/A 1, 8-K/A 1, CERT 1, DEFA14A 1, PRE 14A 1, RW 1, S-4 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-09 | 20:05 ET | [DEF 14A](/filings/0001601485-26-000061.md) | Proxy statement, period 2025-12-31 | 0001601485-26-000061 |
| 2026-09-14 | 20:03 ET | [8-K](/filings/0001601485-26-000058.md) | 5.08 Item not in the standard list; 8.01 Other events | 0001601485-26-000058 |
| 2026-08-13 | 20:08 ET | [10-Q](/filings/0001601485-26-000056.md) | Quarterly report, period 2026-06-30 | 0001601485-26-000056 |
| 2026-08-13 | 20:06 ET | [8-K](/filings/0001601485-26-000055.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001601485-26-000055 |
| 2026-07-02 | 10:20 ET | [8-K](/filings/0001104659-26-080058.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-080058 |
| 2026-06-24 | 20:05 ET | [8-K](/filings/0001601485-26-000050.md) | 7.01 Regulation FD disclosure | 0001601485-26-000050 |
| 2026-06-17 | 12:03 ET | [8-K](/filings/0001601485-26-000048.md) | 8.01 Other events | 0001601485-26-000048 |
| 2026-06-15 | 13:21 ET | [8-K](/filings/0001601485-26-000046.md) | 8.01 Other events | 0001601485-26-000046 |
| 2026-05-11 | 20:12 ET | [10-Q](/filings/0001601485-26-000042.md) | Quarterly report, period 2026-03-31 | 0001601485-26-000042 |
| 2026-05-11 | 20:09 ET | [8-K](/filings/0001601485-26-000041.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001601485-26-000041 |
| 2026-04-29 | 20:06 ET | [10-K/A](/filings/0001601485-26-000035.md) | Annual report, amended, period 2025-12-31 | 0001601485-26-000035 |
| 2026-03-16 | 13:19 ET | [8-K](/filings/0001601485-26-000032.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement | 0001601485-26-000032 |
| 2026-03-12 | 20:24 ET | [10-K](/filings/0001601485-26-000027.md) | Annual report, period 2025-12-31 | 0001601485-26-000027 |
| 2026-03-12 | 20:08 ET | [8-K](/filings/0001601485-26-000026.md) | 2.02 Results of operations | 0001601485-26-000026 |
| 2025-11-13 | 21:08 ET | [10-Q](/filings/0001601485-25-000124.md) | Quarterly report, period 2025-09-30 | 0001601485-25-000124 |
| 2025-11-13 | 21:04 ET | [8-K](/filings/0001601485-25-000123.md) | 2.02 Results of operations | 0001601485-25-000123 |
| 2025-09-17 | 12:16 ET | [8-K](/filings/0001193125-25-205522.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-205522 |
| 2025-08-12 | 12:01 ET | [8-K](/filings/0001601485-25-000114.md) | 8.01 Other events | 0001601485-25-000114 |
| 2025-08-07 | 20:49 ET | [10-Q](/filings/0001601485-25-000111.md) | Quarterly report, period 2025-06-30 | 0001601485-25-000111 |
| 2025-08-07 | 20:33 ET | [8-K](/filings/0001601485-25-000108.md) | 2.02 Results of operations | 0001601485-25-000108 |
| 2025-08-05 | 11:08 ET | [8-K](/filings/0001601485-25-000099.md) | 8.01 Other events | 0001601485-25-000099 |
| 2025-06-04 | 21:06 ET | [SCHEDULE 13D/A](/filings/0000950170-25-081739.md) | Ownership report, active investor, amended | 0000950170-25-081739 |
| 2025-06-04 | 12:03 ET | [8-K](/filings/0001601485-25-000096.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001601485-25-000096 |
| 2025-05-20 | 12:06 ET | [8-K](/filings/0001601485-25-000076.md) | 5.07 Shareholder vote results | 0001601485-25-000076 |
| 2025-05-13 | 20:31 ET | [10-Q](/filings/0001601485-25-000074.md) | Quarterly report, period 2025-03-31 | 0001601485-25-000074 |
| 2025-05-13 | 20:27 ET | [8-K](/filings/0001601485-25-000072.md) | 2.02 Results of operations | 0001601485-25-000072 |
| 2025-04-09 | 20:18 ET | [DEF 14A](/filings/0001601485-25-000062.md) | Proxy statement, period 2025-04-09 | 0001601485-25-000062 |
| 2025-03-31 | 11:07 ET | [10-K](/filings/0001601485-25-000049.md) | Annual report, period 2024-12-31 | 0001601485-25-000049 |
| 2025-03-31 | 11:01 ET | [8-K](/filings/0001601485-25-000046.md) | 2.02 Results of operations | 0001601485-25-000046 |
| 2025-03-24 | 11:03 ET | [8-K](/filings/0001601485-25-000022.md) | 5.02 Departure or appointment of officers or directors | 0001601485-25-000022 |
| 2025-03-07 | 21:07 ET | [SCHEDULE 13D/A](/filings/0000950170-25-035497.md) | Ownership report, active investor, amended | 0000950170-25-035497 |
| 2025-03-05 | 21:05 ET | [8-K](/filings/0001601485-25-000018.md) | 3.02 Unregistered sale of equity | 0001601485-25-000018 |
| 2025-01-30 | 14:03 ET | [8-K](/filings/0001193125-25-016455.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-016455 |
| 2025-01-23 | 21:36 ET | [8-K](/filings/0001601485-25-000009.md) | 7.01 Regulation FD disclosure | 0001601485-25-000009 |
| 2025-01-22 | 12:33 ET | [8-K](/filings/0001601485-25-000006.md) | 8.01 Other events | 0001601485-25-000006 |
| 2024-12-12 | 12:05 ET | [8-K](/filings/0001601485-24-000107.md) | 7.01 Regulation FD disclosure; 8.01 Other events | 0001601485-24-000107 |
| 2024-12-03 | 12:10 ET | [8-K](/filings/0001193125-24-269400.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-269400 |
| 2024-11-21 | 21:06 ET | [8-K](/filings/0001601485-24-000083.md) | 5.07 Shareholder vote results | 0001601485-24-000083 |
| 2024-11-13 | 21:11 ET | [10-Q](/filings/0001601485-24-000075.md) | Quarterly report, period 2024-09-30 | 0001601485-24-000075 |
| 2024-11-13 | 21:10 ET | [8-K](/filings/0001601485-24-000074.md) | 2.02 Results of operations | 0001601485-24-000074 |
| 2024-11-07 | 21:27 ET | [8-K](/filings/0001601485-24-000067.md) | 8.01 Other events | 0001601485-24-000067 |
| 2024-11-07 | 14:30 ET | [8-K](/filings/0001601485-24-000063.md) | 8.01 Other events | 0001601485-24-000063 |
| 2024-10-17 | 12:31 ET | [8-K](/filings/0001601485-24-000057.md) | 5.02 Departure or appointment of officers or directors | 0001601485-24-000057 |
| 2024-09-27 | 20:41 ET | [DEF 14A](/filings/0001140361-24-042209.md) | Proxy statement, period 2024-11-07 | 0001140361-24-042209 |
| 2024-08-30 | 12:30 ET | [8-K](/filings/0001140361-24-039592.md) | 5.02 Departure or appointment of officers or directors | 0001140361-24-039592 |
| 2024-08-14 | 21:01 ET | [SC 13D/A](/filings/0001068238-24-000167.md) | Ownership report, active investor, amended | 0001068238-24-000167 |
| 2024-08-13 | 20:58 ET | [10-Q](/filings/0001601485-24-000045.md) | Quarterly report, period 2024-06-30 | 0001601485-24-000045 |
| 2024-08-13 | 20:33 ET | [8-K](/filings/0001601485-24-000042.md) | 2.02 Results of operations | 0001601485-24-000042 |
| 2024-08-12 | 20:24 ET | [8-K](/filings/0001140361-24-036848.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-24-036848 |
| 2024-07-02 | 20:39 ET | [SC 13D/A](/filings/0001068238-24-000141.md) | Ownership report, active investor, amended | 0001068238-24-000141 |

Page 1 of 3. [Older](/companies/eltx/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:14 ET. No prices; not investment advice.